Vistagen to report fiscal year 2025 financial results and host corporate update conference call on june 17, 2025

South san francisco, calif.--(business wire)--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on tuesday, june 17, 2025, at 2:00 p.m. pacific time (5:00 p.m. eastern time) to report results for its fiscal year 2025 ended march 31, 2025, and provide a corporate updat.
VTGN Ratings Summary
VTGN Quant Ranking